热门资讯> 正文
免疫工程报告第一季度结果
2024-05-08 22:50
- Immuneering press release (NASDAQ:IMRX): Q1 GAAP EPS of -$0.49 misses by $0.02.
- Cash, cash equivalents and marketable securities as of March 31 were $71.3M, compared with $85.7M as of December 31, 2023.
- The company expects its cash runway to be sufficient to fund operations into the second half of 2025.
More on Immuneering
- Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
- Seeking Alpha's Quant Rating on Immuneering
- Historical earnings data for Immuneering
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
